MB-106,Cyclophosphamide
fortress biotech,mustang bio
[]
#eha2023: in the waldenstrom macroglobulinemia (wm) cohort of the ongoing phase 1/2 clinical trial, mb-106 demonstrated an 83% overall response rate. no patient has started additional anti-wm treatment after mb-106 treatment. $mbio 
Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.